{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T04:32:46Z","timestamp":1791347566979,"version":"4.3.1"},"reference-count":23,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","license":[{"start":{"date-parts":[[2022,3,11]],"date-time":"2022-03-11T00:00:00Z","timestamp":1646956800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n            <jats:title>Abstract<\/jats:title>\n            <jats:p>Maintaining relative dose intensity (RDI) of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) improves the prognosis of patients with diffuse large B-cell lymphoma (DLBCL). Pegfilgrastim was approved in Japan in November 2014 to prevent febrile neutropenia (FN) and maintain RDI.<\/jats:p>\n            <jats:p>In this retrospective study, we reviewed 334 patients with DLBCL who received 6 or more courses of R-CHOP and analyzed the differences in the RDI, overall survival (OS), and progression-free survival between patients whose treatment started after November 2014 (postapproval group) and those whose treatment started before October 2014 (pre-approval group).<\/jats:p>\n            <jats:p>The incidence of FN was lower (20% vs 38.3%, <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a&lt;\u200a.001) and the RDI of R-CHOP was higher (86.8% vs 67.8%, <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a&lt;\u200a.001) in the postapproval group. Pegfilgrastim was administered to many of these patients (76.8%) and was thought to have contributed to the high RDI maintenance in the postapproval group. Interrupted time-series analysis showed a significant rise of the RDI at the timing of pegfilgrastim approval in patients aged &lt;70\u200ayears (estimated change: 18.1%, <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a&lt;\u200a.001). The 5-year OS (85.7% vs 69.9%, <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.009) and progression-free survival (81.4% vs 64.4%, <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.011) were superior in the postapproval group. However, the differences were not significant in matched-pair analysis matching National Comprehensive Cancer Network-International Prognostic Index scores. Improved survival outcomes in this group were observed only among patients with Ann Arbor stage 3\/4 (5-year OS: 83.7% vs 61.3%, <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.019) and high-risk on the National Comprehensive Cancer Network-International Prognostic Index (5-year OS: 80.7% vs 32.4%, <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.014). Multivariate analysis showed that a high RDI and low lactate dehydrogenase were associated with superior OS (RDI\u200a\u2265\u200a85%, hazard ratio: 0.48, <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.016; lactate dehydrogenase\u200a&gt;\u200ainstitutional upper limit of normal, hazard ratio: 2.38, <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.005).<\/jats:p>\n            <jats:p>The RDI of R-CHOP was able to be maintained at higher levels, the incidence of FN was lower, and significantly better clinical outcomes were achieved in clinically high-risk groups after pegfilgrastim approval. Maintaining a high RDI in R-CHOP by administering pegfilgrastim to those who are likely to have low RDI without it is important for achieving favorable outcomes in patients with DLBCL.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000029028","type":"journal-article","created":{"date-parts":[[2022,4,22]],"date-time":"2022-04-22T11:00:20Z","timestamp":1650625220000},"page":"e29028","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["Impact of pegfilgrastim approval on relative dose intensity and outcomes of R-CHOP for diffuse large B-cell lymphoma"],"prefix":"10.1097","volume":"101","author":[{"given":"Yuka","family":"Morita","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9809-2008","authenticated-orcid":false,"given":"Yusuke","family":"Kanemasa","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Sasaki","sequence":"additional","affiliation":[{"name":"Department of Clinical Research Support, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"An","family":"Ohigashi","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taichi","family":"Tamura","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shohei","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Yagi","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiko","family":"Kageyama","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Omuro","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsu","family":"Shimoyama","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,3,11]]},"reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/1756-9966-28-116","article-title":"Impact of relative dose intensity (RDI) in CHOP combined with rituximab (R-CHOP) on survival in diffuse large B-cell lymphoma","volume":"28","author":"Terada","year":"2009","journal-title":"J Exp Clin Cancer Res"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1007\/s00277-010-0956-7","article-title":"Importance of maintaining the relative dose intensity of CHOP-like regimens combined with rituximab in patients with diffuse large B-cell lymphoma","volume":"89","author":"Hirakawa","year":"2010","journal-title":"Ann Hematol"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"e0123978","DOI":"10.1371\/journal.pone.0123978","article-title":"Differential impact of relative dose-intensity reductions in diffuse large B-cell lymphoma treated with R-CHOP21 or R-CHOP14","volume":"10","author":"Guti\u00e9rrez","year":"2015","journal-title":"PLoS One"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1182\/asheducation-2011.1.498","article-title":"Relapsed\/refractory diffuse large B-cell lymphoma","volume":"2011","author":"Friedberg","year":"2011","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"3158","DOI":"10.1200\/JCO.2006.08.8823","article-title":"Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review","volume":"25","author":"Kuderer","year":"2007","journal-title":"J Clin Oncol"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1185\/030079907X219599","article-title":"Comparison of pegfilgrastim with filgrastim on febrile neutropenia, grade IV neutropenia and bone pain: a meta-analysis of randomized controlled trials","volume":"23","author":"Pinto","year":"2007","journal-title":"Curr Med Res Opin"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1186\/1471-2407-11-404","article-title":"Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: systematic review and meta-analysis","volume":"11","author":"Cooper","year":"2011","journal-title":"BMC Cancer"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1093\/annonc\/mdt226","article-title":"The impact of the granulocyte colony-stimulating factor on chemotherapy dose intensity and cancer survival: a systematic review and meta-analysis of randomized controlled trials","volume":"24","author":"Lyman","year":"2013","journal-title":"Ann Oncol"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1182\/blood-2013-09-524108","article-title":"An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era","volume":"123","author":"Zhou","year":"2014","journal-title":"Blood"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"359","DOI":"10.3109\/10428190109057991","article-title":"Reduced-dose chop therapy for elderly patients with non-Hodgkin's lymphoma","volume":"41","author":"Mori","year":"2001","journal-title":"Leuk Lymphoma"},{"key":"R13-20250504","first-page":"348","article-title":"Interrupted time series regression for the evaluation of public health interventions: a tutorial","volume":"46","author":"Bernal","year":"2017","journal-title":"Int J Epidemiol"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1017\/S0266462303000576","article-title":"Interrupted time series designs in health technology assessment: lessons from two systematic reviews of behavior change strategies","volume":"19","author":"Ramsay","year":"2003","journal-title":"Int J Technol Assess Health Care"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1177\/0013164406294774","article-title":"Identifying autocorrelation generated by various error processes in interrupted time-series regression designs: a comparison of AR1 and portmanteau tests","volume":"67","author":"Huitema","year":"2007","journal-title":"Educ Psychol Meas"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"3199","DOI":"10.1200\/JCO.2015.62.3488","article-title":"Recommendations for the use of WBC growth factors: American Society of Clinical Oncology clinical practice guideline update","volume":"33","author":"Smith","year":"2015","journal-title":"J Clin Oncol"},{"key":"R17-20250504","first-page":"CD003189","article-title":"Granulopoiesis-stimulating factors to prevent adverse effects in the treatment of malignant lymphoma","volume":"2008","author":"Bohlius","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1634\/theoncologist.12-12-1416","article-title":"Elderly cancer patients receiving chemotherapy benefit from first-cycle pegfilgrastim","volume":"12","author":"Balducci","year":"2007","journal-title":"Oncologist"},{"key":"R19-20250504","doi-asserted-by":"crossref","first-page":"08","DOI":"10.1016\/j.ejca.2010.10.013","article-title":"2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours","volume":"47","author":"Aapro","year":"2011","journal-title":"Eur J Cancer"},{"key":"R20-20250504","doi-asserted-by":"crossref","first-page":"12","DOI":"10.6004\/jnccn.2020.0002","article-title":"NCCN guidelines insights: hematopoietic growth factors","volume":"18","author":"Becker","year":"2020","journal-title":"J Natl Compr Canc Netw"},{"key":"R21-20250504","doi-asserted-by":"crossref","first-page":"4302","DOI":"10.1200\/JCO.2004.03.213","article-title":"Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin's lymphoma: a nationwide study","volume":"22","author":"Lyman","year":"2004","journal-title":"J Clin Oncol"},{"key":"R22-20250504","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.jclinepi.2008.08.007","article-title":"Methods for estimating confidence intervals in interrupted time series analyses of health interventions","volume":"62","author":"Zhang","year":"2009","journal-title":"J Clin Epidemiol"},{"key":"R23-20250504","doi-asserted-by":"crossref","first-page":"h2750","DOI":"10.1136\/bmj.h2750","article-title":"Regression based quasi-experimental approach when randomisation is not an option: interrupted time series analysis","volume":"350","author":"Kontopantelis","year":"2015","journal-title":"BMJ"},{"key":"R24-20250504","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1016\/S0140-6736(19)33008-9","article-title":"Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial","volume":"394","author":"Poeschel","year":"2019","journal-title":"Lancet"},{"key":"R25-20250504","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.1200\/JCO.20.00999","article-title":"Positron emission tomography-directed therapy for patients with limited-stage diffuse large B-cell lymphoma: results of Intergroup National Clinical Trials Network Study S1001","volume":"38","author":"Persky","year":"2020","journal-title":"J Clin Oncol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000029028","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T04:01:37Z","timestamp":1746331297000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000029028"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,11]]},"references-count":23,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000029028","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,11]]},"assertion":[{"value":"2021-11-07","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-02-15","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}